|
| Press Releases |
|
 |
|
| Friday, April 23, 2021 |
|
|
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab. more info >> |
|
| Tuesday, April 20, 2021 |
|
|
エーザイ、Lecanemab（BAN2401）の早期アルツハイマー病に対する18カ月の臨床第IIb相試験の結果が査読学術専門誌Alzheimer's Research and Therapy誌に掲載 |
| エーザイ株式会社（代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq: BIIB、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）は、このたび、抗アミロイドB（AB）プロトフィブリル抗体lecanemab（開発コード：BAN2401）による早期アルツハイマー病（早期AD）に対する無作為化、二重盲検、POC（Proof of Concept：創薬概念の検証）臨床第IIb相試験（201試験）別ウィンドウで開きますの結果がAlzheimer’s Research and Therapy誌に掲載されたことをお知らせします。 more info >> |
|
|
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. more info >> |
|
| Wednesday, April 14, 2021 |
|
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
| Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
|
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2021年4月17日から22日までバーチャルで開催される「米国神経学会（American Academy of Neurology）年次総会：AAN2021」において、抗アミロイドB（AB）プロトフィブリル抗体lecanemab（開発品コード：BAN2401）、デュアルオレキシン受容体拮抗剤レンボレキサント（製品名「デエビゴ(R)」、海外製品名「Dayvigo(R)」）および抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、海外製品名「Fycompa(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Monday, April 12, 2021 |
|
|
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、リンパ系フィラリア症（LF）の制圧活動をテーマとして当社が制作したアニメーション動画「Leave No One Behind―顧みられない人々の病気―」が、International Society for Neglected Tropical Diseases （ISNTD）フェスティバルアワード 2021 の「アニメーション賞」を受賞したことをお知らせします。 more info >> |
|
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
| Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
| Wednesday, March 31, 2021 |
|
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
| KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
| Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
| Tuesday, March 30, 2021 |
|
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
| Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Formerra and H.B. Fuller Announce Strategic Partnership to Drive Growth in Advanced Bonding Solutions
Oct 23, 2024 21:00 HKT/SGT
|
|
|
GMG Reaches Major Milestones in THERMAL-XR(R) Test Work
Oct 23, 2024 20:09 HKT/SGT
|
|
|
ヒーローワークス、日本にホテル収益管理ソリューションを供給… 現地パートナー企業を物色
Oct 23, 2024 19:00: JST
|
|
|
Joint Study by Idemitsu Kosan and Mitsubishi Corporation on Low-Carbon Ammonia
Oct 23, 2024 18:15 JST
|
|
|
TANAKA Precious Metals stellt neue Palladiumlegierung TK-SK für Halbleiterprüfsysteme vor
Oct 23, 2024 16:00 HKT/SGT
|
|
|
标普稳定评级支持复星全球化及创新发展
Oct 23, 2024 15:51 HKT/SGT
|
|
|
Stable S&P rating supports Fosun's globalization and innovation
Oct 23, 2024 15:43 HKT/SGT
|
|
|
標普穩定評級支持復星全球化及創新發展
Oct 23, 2024 15:39 HKT/SGT
|
|
|
Hitachi helps First Bus move closer to 2035 Net Zero goal
Oct 23, 2024 16:08 JST
|
|
|
Asian Actuarial Conference 2024 Kicks Off in Hong Kong to Great Acclaims
Oct 23, 2024 15:04 HKT/SGT
|
|
|
2024年亞洲精算大會於香港隆重揭幕
Oct 23, 2024 14:49 HKT/SGT
|
|
|
三大優質資產注入 金涌投資業務多元化發展
Oct 23, 2024 14:41 HKT/SGT
|
|
|
三大优质资产注入 金涌投资业务多元化发展
Oct 23, 2024 14:34 HKT/SGT
|
|
|
Valuufy、千本倖生博士を取締役会長に任命、サステナビリティ評価に新時代到来を示唆
Oct 23, 2024 14:00: JST
|
|
|
Hong Kong International Optical Fair to open in November
Oct 23, 2024 13:21 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
